For: | Saif MW, Relias V, Syrigos K, Gunturu KS. Incidence and management of ZIv-aflibercept related toxicities in colorectal cancer. World J Clin Oncol 2014; 5(5): 1028-1035 [PMID: 25493238 DOI: 10.5306/wjco.v5.i5.1028] |
---|---|
URL: | https://www.wjgnet.com/2218-4333/full/v5/i5/1028.htm |
Number | Citing Articles |
1 |
Sabina Palma, Ariel O. Zwenger, María V. Croce, Martín C. Abba, Ezequiel Lacunza. From Molecular Biology to Clinical Trials: Toward Personalized Colorectal Cancer Therapy. Clinical Colorectal Cancer 2016; 15(2): 104 doi: 10.1016/j.clcc.2015.11.001
|
2 |
S. Baillif, B. Levy, J.-F. Girmens, S. Dumas, R. Tadayoni. Tolérance systémique des injections intravitréennes d’anti-VEGF. Journal Français d'Ophtalmologie 2018; 41(3): 271 doi: 10.1016/j.jfo.2017.11.006
|
3 |
Kei Muro, Taylor Salinardi, Arvind Rup Singh, Teresa Macarulla. Safety of Aflibercept in Metastatic Colorectal Cancer: A Literature Review and Expert Perspective on Clinical and Real-World Data. Cancers 2020; 12(4): 844 doi: 10.3390/cancers12040844
|
4 |
Vaishali Gupta, Taha Bharmal, Vineeta Dixit, Naveen Kumar Vishvakarma, Atul Kumar Tiwari, Dhananjay Shukla, Shirish Shukla. Colon Cancer Diagnosis and Therapy. 2021; : 219 doi: 10.1007/978-3-030-63369-1_11
|
5 |
Javier David Benitez Fuentes, Alfonso Lopez de Sa Lorenzo, Alberto Elpidio Calvo Elias, Carmen Toledano Rojas, Monica Granja Ortega. Perforation of the Nasal Septum in a Colorectal Cancer Patient Treated With Aflibercept: A Case Report. Cureus 2022; doi: 10.7759/cureus.26780
|
6 |
Robert Meehan, Shivaani Kummar, Khanh Do, Geraldine O'Sullivan Coyne, Lamin Juwara, Jennifer Zlott, Larry Rubinstein, James H. Doroshow, Alice P. Chen. A Phase I Study of Ganetespib and Ziv-Aflibercept in Patients with Advanced Carcinomas and Sarcomas. The Oncologist 2018; 23(11): 1269 doi: 10.1634/theoncologist.2018-0203
|